
	March 31, 2026								December 31, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,623)	$	—	$	2,097	$	10,720	$	(8,448)	$	—	$	2,272
Intangible asset – axicabtagene ciloleucel	7,110		(3,229)		—		3,881		7,110		(3,127)		—		3,983
Intangible asset – Trodelvy	11,730		(4,434)		—		7,296		11,730		(4,164)		—		7,566
Intangible asset – Hepcludex	845		(437)		—		408		845		(415)		—		430
Other	1,458		(1,059)		—		400		1,483		(1,056)		—		428
Total finite-lived assets	31,863		(17,782)		—		14,082		31,888		(17,211)		—		14,678
Indefinite-lived assets – IPR&D(1)	2,300		—		—		2,300		2,300		—		—		2,300
Total intangible assets	$	34,163	$	(17,782)	$	—	$	16,382	$	34,188	$	(17,211)	$	—	$	16,978

(1) The Indefinite-lived assets – IPR&D balance as of March 31, 2026 was comprised of $1.75 billion related to sacituzumab govitecan-hziy for NSCLC and $550 million related to bulevirtide.